Objective: To evaluate the efficacy of oral administration of resveratrol in association with feverfew (RevifastDol®, S&R Farmaceutici S.p.A., Italy) in the treatment of primary dysmenorrhea.
Methods: This study was based on a retrospective analysis of a prospectively collected database including 30 women of reproductive age suffering primary dysmenorrhea. Patients received RevifastDol® (two tablets per day for 6 months) starting three days before the beginning of the menstrual cycle and each day during the menstrual period. The intensity of dysmenorrhea was assessed by using a 10-cm visual analogue scale. The short-form health survey (SF-36) was used to investigate the quality of life.
Results: At 6-month follow up, 73.3% of the patients were either satisfied or very satisfied with the treatment. Since the first month and during all the study period, there was a significant amelioration in the intensity of dysmenorrhea compared with baseline (p < 0.05). At 6-month follow-up there was a significant reduction in the number of analgesic pills taken each day during the menstrual period and quality of life significantly improved.
Our articles most useful
Beth Turner, Charlotte Garrett and Anja Wittkowski
Published : February 13, 2018
Women's Health Research
Yinjia Guo, Min Zhao, Victoria Rutten, Yifei Gao, Arier Lee, Qi Chen
Published : November 22, 2017
Women's Health Research